The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II study of selective HDAC6 inhibition with KA2507 for second-line treatment of advanced biliary tract cancer (ABC-11).
 
John A. Bridgewater
Honoraria - Merck Serono; SERVIER
Consulting or Advisory Role - AstraZeneca; Basilea; Bayer; Incyte; Merck Serono; Merck Serono; Roche; SERVIER
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Celgene
Research Funding - Amgen
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Bristol-Myers Squibb/Medarex; Merck Serono; MSD Oncology; SERVIER
 
Philip Beer
Employment - Cambridge Cancer Genomics; Karus Therapeutics; OncoDNA
Stock and Other Ownership Interests - Karus Therapeutics
 
Jennifer Bendall
Employment - Karus Therapeutics; PsiOxus Therapeutics
 
Hakim-Moulay Dehbi
No Relationships to Disclose
 
Marian Duggan
No Relationships to Disclose
 
Michelle Hung
No Relationships to Disclose
 
Justine King
Employment - Karus Therapeutics
Stock and Other Ownership Interests - Karus Therapeutics
 
Hilary McElwaine-Johnn
Employment - Karus Therapeutics; PsiOxus Therapeutics
Leadership - Karus Therapeutics; PsiOxus Therapeutics
Stock and Other Ownership Interests - Karus Therapeutics; PsiOxus Therapeutics; Vantia
Consulting or Advisory Role - Vantia
 
Laura White
No Relationships to Disclose